In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs among its membership.
In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs among its membership.
Vizient’s membership currently spends approximately $67 billion on drugs annually, and with a projected 4.28% of drug price inflation, these members are expected to spend another $3 billion annually, even before considering cost increases for new drugs or volume changes.
The top 5 drugs by total spending among Vizient’s membership are adalimumab, infliximab, rituximab, etanercept, and pegfilgrastim, all of which have FDA-approved biosimilars, although only infliximab and pegfilgrastim biosimilars are yet available in the US market. Among these drugs, adalimumab, etanercept, infliximab, and rituximab are all projected to have some of the largest increases in price over the coming year.
As patents for reference products begin to expire, and as more biosimilars are launching in the US market, Vizient says that adopting biosimilars is critical to “combat the costs of these therapies.” In the interest of fostering adoption, Vizient has convened a biosimilars task force to create resources that will help members evaluate biosimilars for formulary inclusion as soon as they launch.
The company has also established a resource webpage for its members that includes evidence-based clinical information on biosimilars, including a soon-to-be-launched financial evaluation tool that members will be able to use to assess the cost and reimbursement impact of adopting different biosimilar-related strategies.
Finally, Vizient says that the market for oncology biosimilars will be “the true test” of whether a biosimilars market in the United States can be sustained, and “it is critically important that we focus our attention on supporting biosimilar evaluation and uptake,” given that spending on rituximab, bevacizumab, trastuzumab, and pegfilgrastim alone account for approximately $14 billion in member spending each year.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.